Benefits of using ramucirumab plus docetaxel in 2nd line NSCLC

Benefits of using ramucirumab plus docetaxel in 2nd line NSCLC

obr

1 year
42 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
David R. Gandara, MD, talks about the benefits of using Cyramza® (ramucirumab) plus docetaxel verus docetaxel alone in 2nd line NSCLC at Annual Meeting 2018.
Up Next Autoplay